{"product_id":"lelipel-4mg","title":"LELIPEL 4mg","description":"\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"col-12 col-md-8 offset-md-2\"\u003e\u003cmain id=\"main\" class=\"site-main content-area\"\u003e\n\u003carticle id=\"post-2744\" class=\"post-2744 portfolio type-portfolio status-publish has-post-thumbnail hentry portfolio-types-paediatric-health portfolio-types-products\"\u003e\n\u003cdiv class=\"entry-content pix-mb-20\"\u003e\n\u003cp dir=\"rtl\"\u003eهذه المادة حاصلة على موافقة هيئة الدواء المصرية برقم SF0327OA5807 \/ 032026 تاريخ الانتهاء 16\/03\/2027 برجاء إبلاغ الإدارة العامة لتنظيم مواد التسويق والإعلان عن أي مواد دعائية أو تعليمية أو توعوية مخالفة لا تحتوي على هذه البيانات من خلال خدمة الإبلاغ عن مواد دعائية دوائية غير ملائمة www.edaegypt.gov.eg\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003c\/main\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003eLELIPEL\u003c\/strong\u003e (montelukast sodium) is a selective and orally active leukotriene receptor antagonist that specifically inhibits cysteinyl leukotriene CysLT1 receptor.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCategory:\u003c\/strong\u003e Paediatric Health\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eActive Ingredients:\u003c\/strong\u003e Montelukast Sodium\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eAction:\u003c\/strong\u003e Selective Leukotrienes receptor antagonist\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eIndications:\u003c\/strong\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eIndicated in the treatment of asthma as add-on therapy in those 6 months to 5 years old patients and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom \"as-needed\" short acting beta agonists provide inadequate clinical control of asthma.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eIndicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMay also be an alternative treatment option to low dose inhaled corticosteroids for 2 to 5 years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Globe","offers":[{"title":"Default Title","offer_id":45638449528993,"sku":null,"price":0.0,"currency_code":"EGP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0693\/7529\/5649\/files\/l_1.png?v=1768894757","url":"https:\/\/www.globe-international.com\/ar\/products\/lelipel-4mg","provider":"Globe","version":"1.0","type":"link"}